498 related articles for article (PubMed ID: 31599488)
41. FDG PET/CT in Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease.
Ngo VT; Wassef HR
Clin Nucl Med; 2022 Aug; 47(8):732-735. PubMed ID: 35293357
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
43. Solitary Adult Rib Langerhans Cell Histiocytosis Evaluated by 18F-FDG PET/CT.
Wang Q; Yang S; Tang W; Liu H; Chen Y
Clin Nucl Med; 2021 Sep; 46(9):756-758. PubMed ID: 33795592
[TBL] [Abstract][Full Text] [Related]
44. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas.
van Egmond SL; Piscaer V; Janssen LM; Stegeman I; Hobbelink MG; Grolman W; Terhaard CH
Acta Oncol; 2016; 55(9-10):1099-1106. PubMed ID: 27219720
[TBL] [Abstract][Full Text] [Related]
45. FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients.
Sharp SE; Shulkin BL; Gelfand MJ; McCarville MB
Pediatr Radiol; 2017 Dec; 47(13):1800-1808. PubMed ID: 28887617
[TBL] [Abstract][Full Text] [Related]
46. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
47. Skeletal staging in Langerhans cell histiocytosis: a multimodality imaging review.
Rajakulasingam R; Siddiqui M; Michelagnoli M; Saifuddin A
Skeletal Radiol; 2021 Jun; 50(6):1081-1093. PubMed ID: 33215231
[TBL] [Abstract][Full Text] [Related]
48. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
49. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
50. Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
Kaumanns A; König D; Hojski A; Cattaneo M; Chirindel A; Wiese M; Tamm M; Lardinois D; Rothschild SI
Lung Cancer; 2022 Nov; 173():14-20. PubMed ID: 36108578
[TBL] [Abstract][Full Text] [Related]
51. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
[TBL] [Abstract][Full Text] [Related]
52. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
53. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
54. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
55. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
56. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
57. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
58. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
59. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of
Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
